Abstract
Contact tracing, where exposed individuals are followed up to break ongoing transmission chains, is a key pillar of outbreak response for many infectious disease outbreaks, such as Ebola and SARS-CoV-2. Unfortunately, these systems are not fully effective, and cases can still go undetected as people may not know or remember all of their contacts or contacts may not be able to be traced. A large proportion of undetected cases suggests poor contact tracing and surveillance systems, which could be a potential area of improvement for a disease response. In this paper, we present a novel method for estimating the proportion of cases that are not detected during an outbreak. Our method uses next generation matrices that are parameterized by linked contact tracing and case line-lists. We use this method to investigate the proportion of undetected cases in two case studies: the SARS-CoV-2 outbreak in New Zealand during 2020 and the West African Ebola outbreak in Guinea during 2014. We estimate that only 6% of SARS-CoV-2 cases were not detected in New Zealand (95% credible interval: 1.31 – 16.7%), but over 60% of Ebola cases were not detected in Guinea (95% credible interval: 15 - 90%).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
All authors acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth * Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union; and acknowledge funding by Community Jameel. HJTU also acknowledges funding from Imperial College, London for her fellowship. CAD also acknowledge the NIHR Health Protection Research Unit in Emerging and Zoonotic Infections.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
None required
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Abbreviations
- NZ
- New Zealand
- NGM
- next generation matrices
- R0
- basic reproduction number
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos